CN112204011A - 一种甲磺酸乐伐替尼新晶型及其制备方法 - Google Patents
一种甲磺酸乐伐替尼新晶型及其制备方法 Download PDFInfo
- Publication number
- CN112204011A CN112204011A CN201980032672.1A CN201980032672A CN112204011A CN 112204011 A CN112204011 A CN 112204011A CN 201980032672 A CN201980032672 A CN 201980032672A CN 112204011 A CN112204011 A CN 112204011A
- Authority
- CN
- China
- Prior art keywords
- degrees
- mesylate
- crystal form
- lenvatinib
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- ZSPLOATUDIRNAS-PPHPATTJSA-N levofloxacin mesylate Chemical compound CS(O)(=O)=O.C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 ZSPLOATUDIRNAS-PPHPATTJSA-N 0.000 title description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims abstract description 44
- 239000003814 drug Substances 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 238000002425 crystallisation Methods 0.000 claims description 7
- 230000008025 crystallization Effects 0.000 claims description 7
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims 1
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 description 25
- 239000007787 solid Substances 0.000 description 23
- 238000012360 testing method Methods 0.000 description 19
- 229960001429 lenvatinib mesylate Drugs 0.000 description 16
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 11
- 229960003784 lenvatinib Drugs 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000000706 filtrate Substances 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 238000002411 thermogravimetry Methods 0.000 description 7
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000012046 mixed solvent Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 240000006570 Euonymus japonicus Species 0.000 description 1
- 235000016796 Euonymus japonicus Nutrition 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 238000002447 crystallographic data Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- JUWSSMXCCAMYGX-UHFFFAOYSA-N gold platinum Chemical compound [Pt].[Au] JUWSSMXCCAMYGX-UHFFFAOYSA-N 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种甲磺酸乐伐替尼的新晶型、其制备方法及制备治疗癌症的药物中的用途。
Description
PCT国内申请，说明书已公开。
Claims (10)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018105570620 | 2018-06-01 | ||
| CN201810557062 | 2018-06-01 | ||
| PCT/CN2019/089398 WO2019228485A1 (zh) | 2018-06-01 | 2019-05-31 | 一种甲磺酸乐伐替尼新晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112204011A true CN112204011A (zh) | 2021-01-08 |
Family
ID=68698706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980032672.1A Pending CN112204011A (zh) | 2018-06-01 | 2019-05-31 | 一种甲磺酸乐伐替尼新晶型及其制备方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US11634388B2 (zh) |
| CN (1) | CN112204011A (zh) |
| WO (1) | WO2019228485A1 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111233762B (zh) * | 2020-02-20 | 2021-12-28 | 天津理工大学 | 一种乐伐替尼与对羟基苯甲酸共晶及其制备方法 |
| CN114174264B (zh) * | 2020-04-24 | 2024-02-27 | 成都苑东生物制药股份有限公司 | 一种甲磺酸仑伐替尼晶型xi及其制备方法 |
| CN111793027B (zh) * | 2020-08-07 | 2021-12-03 | 天津理工大学 | 一种乐伐替尼与苯甲酸的共晶及其制备方法 |
| CN114213322B (zh) * | 2022-01-05 | 2023-11-07 | 中国药科大学 | 甲磺酸仑伐替尼没食子酸共晶及其制备方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101233111A (zh) * | 2005-06-23 | 2008-07-30 | 卫材R&D管理有限公司 | 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法 |
| CN101337931A (zh) * | 2003-12-25 | 2009-01-07 | 卫材R&D管理有限公司 | 喹啉羧酰胺的甲磺酸盐的醋酸合物的结晶(i)及其制备方法 |
| WO2016184436A1 (zh) * | 2015-05-21 | 2016-11-24 | 苏州晶云药物科技有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
| CN106660964A (zh) * | 2014-08-28 | 2017-05-10 | 卫材R&D管理有限公司 | 高纯度喹啉衍生物及其生产方法 |
| CN107266363A (zh) * | 2016-04-06 | 2017-10-20 | 杭州华东医药集团新药研究院有限公司 | 甲磺酸乐伐替尼药物杂质的制备方法 |
-
2019
- 2019-05-31 WO PCT/CN2019/089398 patent/WO2019228485A1/zh active Application Filing
- 2019-05-31 CN CN201980032672.1A patent/CN112204011A/zh active Pending
- 2019-05-31 US US17/059,708 patent/US11634388B2/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101337931A (zh) * | 2003-12-25 | 2009-01-07 | 卫材R&D管理有限公司 | 喹啉羧酰胺的甲磺酸盐的醋酸合物的结晶(i)及其制备方法 |
| CN101233111A (zh) * | 2005-06-23 | 2008-07-30 | 卫材R&D管理有限公司 | 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法 |
| CN106660964A (zh) * | 2014-08-28 | 2017-05-10 | 卫材R&D管理有限公司 | 高纯度喹啉衍生物及其生产方法 |
| WO2016184436A1 (zh) * | 2015-05-21 | 2016-11-24 | 苏州晶云药物科技有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
| CN107266363A (zh) * | 2016-04-06 | 2017-10-20 | 杭州华东医药集团新药研究院有限公司 | 甲磺酸乐伐替尼药物杂质的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| US11634388B2 (en) | 2023-04-25 |
| WO2019228485A1 (zh) | 2019-12-05 |
| US20210214309A1 (en) | 2021-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112204011A (zh) | 一种甲磺酸乐伐替尼新晶型及其制备方法 | |
| US20120101277A1 (en) | Crystalline form of posaconazole | |
| WO2018045993A1 (zh) | 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 | |
| CN114728954B (zh) | Tropifexor的新晶型及其制备方法 | |
| CN114907325A (zh) | Belumosudil甲磺酸盐的晶型及其制备方法和用途 | |
| EP4011869B1 (en) | Crystal form d of pyrazine-2(1h)-ketone compound and preparation method therefor | |
| EP3896063A1 (en) | Salt of syk inhibitor and crystalline form thereof | |
| US20240182466A1 (en) | A Crystal Form of a Fluorine-substituted Pyridopyrazole Compound and a Preparation Method Thereof | |
| EP3178821B1 (en) | 6-aryl amino pyridone formamide compound crystal and preparation method therefor | |
| CN111032627B (zh) | 一种雌激素受体抑制剂的晶型及其制备方法 | |
| CN114728955A (zh) | Tropifexor的新晶型及其制备方法 | |
| CN111057092A (zh) | 一种三(2-甲基-2-苯基丙基)锡3-氨基哌嗪酸酯配合物及其制备方法与应用 | |
| CN111138480A (zh) | 一种三环己基锡喹啉-4-甲酸酯配合物的制备方法与应用 | |
| CN114773211B (zh) | 一种葡甲胺盐的晶型、其制备方法及应用 | |
| TW201945359A (zh) | 一種c-MET抑制劑的晶型及其鹽型和製備方法 | |
| CN114644615B (zh) | 一种吲唑类衍生物的结晶形式及其制备方法 | |
| CN112250658B (zh) | 一种甲酰化双环醇及其制备方法 | |
| WO2024131882A1 (zh) | 一种吡啶多取代化合物的盐型、晶型及其制备方法 | |
| CN109053717B (zh) | 一种罗格列酮龙胆酸盐及其制备方法 | |
| RU2787767C2 (ru) | Кристалл производного бензоксазола | |
| WO2023185638A1 (zh) | 一种喹啉衍生物的晶型及其制备方法 | |
| CN109096310A (zh) | 一种1/4水头孢西丁钠化合物 | |
| CN111718340A (zh) | 氘代Palbociclib化合物的晶型、制备方法及应用 | |
| CN117794913A (zh) | 嘧啶衍生物及其药学上可接受的盐的多晶型物和应用 | |
| KR20240004588A (ko) | 피롤로피리미딘류 화합물의 결정형 및 이의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210108 |